also known gatekeeper mutation epidermal growth factor receptor egfr mutation substitutes threonine methionine position exon affecting atp binding pocket egfr kinase domain threonine small polar amino acid methionine larger nonpolar amino acid rather directly blocking inhibitor binding active site increases affinity atp inhibitors outcompeted irreversible covalent inhibitors neratinib overcome acquired resistance egfr tyrosine kinase inhibitors tki caused mutation atp binding pocket egfr kinase domain involving substitution small polar threonine residue large nonpolar methionine residue november us fda granted accelerated approval osimertinib tagrisso treatment patients metastatic epidermal growth factor receptor egfr mutationpositive nonsmall cell lung cancer nsclc detected fdaapproved test progressed egfr tki biochemistry article stub help wikipedia expanding genetics article stub help wikipedia expanding